Zephyrnet Logo

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Date:

Home > Press > Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021.

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results


Pasadena. CA | Posted on April 16th, 2021

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company’s website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3080187.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 3080187.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the continuing impact of the COVID-19 pandemic, the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361
www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New nanoscale device for spin technology: Spin waves could unlock the next generation of computer technology, a new component allows physicists to control them April 16th, 2021

New tech builds ultralow-loss integrated photonic circuits April 16th, 2021

Oregon scientists create mechanism to precisely control soundwaves in metamaterials: Theoretical modeling shows that designer materials incorporating drum-like membranes allow precise stoppage and reversal of sound pulses April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

French & Swiss Scientists Demonstrate ‘All-in-One’ Technique that Could Accelerate Phage-Therapy Diagnosis: Lensless Imaging System Affirms Phage Therapy’s Value in Treating Serious Infection, Tracks Phage Resistance and Could Easily Be Implemented in Compact Devices at Phage Lab April 13th, 2021

Energy transmission by gold nanoparticles coupled to DNA structures April 9th, 2021

A new agent for the brain diseases: mRNA April 9th, 2021

Announcements

New tech builds ultralow-loss integrated photonic circuits April 16th, 2021

Oregon scientists create mechanism to precisely control soundwaves in metamaterials: Theoretical modeling shows that designer materials incorporating drum-like membranes allow precise stoppage and reversal of sound pulses April 16th, 2021

FSU engineers improve performance of high-temperature superconductor wires April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Financial Reports

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

CEA-Leti Envisions Widespread Use of LiDAR Systems Based on Integrated Optical Phased Arrays (OPAs): OPAs with Solid-State Beam Steering Can Reduce the Cost and Size of LiDAR Systems & Improve Performance; Results Reported at Photonics West 2021 March 9th, 2021

CEA-Leti Announces 16 Papers to Be Presented At Photonics West 2021 and a Virtual Workshop on March 25 March 3rd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

French & Swiss Scientists Demonstrate ‘All-in-One’ Technique that Could Accelerate Phage-Therapy Diagnosis: Lensless Imaging System Affirms Phage Therapy’s Value in Treating Serious Infection, Tracks Phage Resistance and Could Easily Be Implemented in Compact Devices at Phage Lab April 13th, 2021

Energy transmission by gold nanoparticles coupled to DNA structures April 9th, 2021

A new agent for the brain diseases: mRNA April 9th, 2021

Coinsmart. Beste Bitcoin-Börse in Europa
Source: http://www.nanotech-now.com/news.cgi?story_id=56648

spot_img

Latest Intelligence

spot_img